VALNEVA SE ADR
NASDAQ: VALN (Valneva SE)
Last update: 1 hour ago6.43
-0.15 (-2.28%)
| Previous Close | 6.58 |
| Volume | 22,286 |
| Price / Sales | 3.51 |
| Price / Book | 6.58 |
| 52 Weeks Range |
| Profit Margin | -43.21% |
| Operating Margin (TTM) | -12.11% |
| Diluted EPS (TTM) | -1.31 |
| Quarterly Revenue Growth (YOY) | 50.30% |
| Total Debt/Equity (MRQ) | 120.48% |
| Current Ratio (MRQ) | 2.70 |
| Operating Cash Flow (TTM) | -46.93 M |
| Levered Free Cash Flow (TTM) | -122.62 M |
| Return on Assets (TTM) | -19.19% |
| Return on Equity (TTM) | -44.11% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Valneva SE | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.00 |
|
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Institutions | 0.82% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| General American Investors Co Inc | 30 Jun 2026 | 354,361 |
| Vsm Wealth Advisory, Llc | 30 Jun 2026 | 10,000 |
| Steigerwald, Gordon & Koch Inc. | 30 Jun 2026 | 1,250 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |